Article Text

Download PDFPDF

184 UPLIFT (ENGOT-ov67/GOG-3048) a pivotal cohort of upifitamab rilsodotin, a NaPi2b-directed ADC in platinum-resistant ovarian cancer
  1. N Concin1,
  2. E Hamilton2,3,
  3. LM Randall4,
  4. S Banerjee5,
  5. L Mileshkin6,
  6. RL Coleman7,8,
  7. B Monk9,10,11,
  8. MR Mirza12,13,14,15,16,17,
  9. A Savarese18,
  10. I Ray-Coquard19,
  11. JA Perez Fidalgo20,
  12. P Bernardo21,
  13. E Putiri21,
  14. R Burger21,
  15. R Mosher21,
  16. D Richardson22,
  17. D Cibula23,
  18. R Madry24,
  19. R Chekerov25 and
  20. T Van Gorp26
  1. 1Medical University of Innsbruck, Austria, Department of Obstetrics and Gynaecology , Innsbruck, Austria
  2. 2Sarah Cannon Research Institute, Nashville, United States
  3. 3Tennessee Oncology, Nashville, United States
  4. 4VCU Health System, MCV Physicians, Department of Obstetrics and Gynecology Oncology, Richmond, United States
  5. 5The Royal Marsden Nhs Trust, Institute of Cancer Research, London, United Kingdom
  6. 6Peter MacCallum Cancer Centre, Melbourne, Australia
  7. 7Texas Oncology-The Woodlands, The Woodlands, United States
  8. 8GOG Foundation
  9. 9Arizona Oncology , US Oncology Network, Phoenix, United States
  10. 10US Oncology, Gynecologic Program
  11. 11GOG Partners
  12. 12Rigshospitalet, København, Denmark
  13. 13Nordic Society of Gynecological Oncology, Clinical Trial Unit, Denmark
  14. 14European Network of Gynecological Trial groups
  15. 15Gynecologic Cancer Inter-Group
  16. 16European Society of Medical Oncology
  17. 17European Society of Gynecological Oncology
  18. 18Regina Elena National Cancer Institute, Rome, Italy
  19. 19Léon Bérard Center, Lyon, France
  20. 20Hospital Clínic Universitari, València, Spain
  21. 21Mersana Therapeutics Inc, Cambridge, United States
  22. 22OU Health Stephenson Cancer Center, Oklahoma City, United States
  23. 23Charles University, Czech Republic
  24. 24Poznan University of Medical Sciences, Poznań, Poland
  25. 25Charité – Universitätsmedizin Berlin, Berlin, Germany
  26. 26Uz Leuven, oncology, Leuven, Belgium


Introduction/Background*Upifitamab rilsodotin (XMT-1536; UpRi), is a first-in-class Dolaflexin antibody-drug conjugate targeting NaPi2b, a sodium-dependent phosphate transport protein broadly expressed in solid tumors including high-grade serous epithelial ovarian cancer (OC). UpRi’s safety and efficacy are being evaluated in a Phase I study (NCT03319628). Preliminary antitumor activity from an expansion cohort of heavily-pretreated OC patients has been reported (Hamilton et al, ESMO 2020). A data-cut of December 2020 demonstrated an ORR of 39% including 2 CRs and DCR of 81% in 26 OC patients with high NaPi2b expression (TPS ≥75). The 2 patients achieving CR had previously been treated with bevacizumab and PARPi (Richardson et al, ASCO 2021, TPS5607). The prevalence of a TPS ≥75 is greater than 60%.

PROC remains a serious unmet medical need as available treatment options provide modest benefit of no more than 12% ORR and median OS less than 12 months. Based on encouraging anti-tumor activity of UpRi, UPLIFT was designed as a Phase 2 single-arm registration strategy for PROC as part of the ongoing study.

Methodology The UPLIFT cohort is enrolling patients with platinum resistant high grade serous ovarian, fallopian tube and primary peritoneal cancer with up to 4 prior lines of therapy. Prior bevacizumab is required for patients with 1 or 2 prior lines of therapy but is not required for patients with 3-4 prior lines of therapy. UPLIFT will enroll approximately 180 patients globally for 100 patients with high NaPi2b expression. UpRi is dosed intravenously at 43 mg/m2 every 4 weeks. Patients may enroll regardless of NaPi2b expression and regardless of baseline peripheral neuropathy. Baseline tumor samples (fresh or archived) will be collected for retrospective tumor tissue evaluation of NaPi2b expression.

Result(s)*The primary objective is assessment of objective response rate in patients with high NaPi2b expression. The cut-off for high NaPi2b expression is TPS ≥75 and was based on data from the expansion cohort. Secondary endpoints include objective response rate in the overall population, duration of response, and adverse events.

Conclusion*This study is being conducted in collaboration with ENGOT and GOG. Patients will be enrolled globally. (NCT03319628).

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.